Desmopressin
FDA ApprovedAlso known as: DDAVP, Stimate, Nocdurna, 1-deamino-8-D-arginine vasopressin
Hormonal & RenalLast reviewed: April 28, 2026
A synthetic analog of vasopressin (antidiuretic hormone) FDA-approved for diabetes insipidus, bedwetting, and hemophilia A. One of the most widely prescribed peptide drugs globally.
Mechanism of Action
Selectively activates V2 vasopressin receptors in the kidney collecting ducts, increasing water reabsorption and concentrating urine. Also releases von Willebrand factor and Factor VIII from endothelial stores, aiding blood clotting.
Common Uses
- Central diabetes insipidus
- Nocturnal enuresis (bedwetting)
- Hemophilia A (mild)
- Von Willebrand disease
- Nocturia
Known Risks
- Hyponatremia (water intoxication — serious)
- Headache
- Nausea
- Fluid retention
- Seizures if sodium drops too low
Regulatory Status
FDA-approved in multiple formulations: DDAVP (nasal spray, injection, tablets), Stimate (nasal spray for bleeding disorders), Nocdurna (sublingual for nocturia). Generic available.
Common Protocols
Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.
Intranasal / Oral / Subcutaneous
Typical Dose
10–40 mcg intranasal; 0.1–0.4 mg oral
Frequency
1–3x daily depending on indication
Cycle Length
Ongoing for chronic conditions
Restrict fluid intake to prevent hyponatremia. Monitor sodium levels. Dose varies significantly by indication.
Related Compounds
Research References
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.